Global Renal Insufficiency Market - 2023-2030

Global Renal Insufficiency Market - 2023-2030

Global Renal Insufficiency Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

A condition known as renal insufficiency, often referred to as kidney insufficiency or kidney failure, occurs when the kidneys are unable to efficiently carry out their essential tasks, which reduces their capacity to filter waste materials and extra fluids from the circulation. This may cause the body to accumulate waste and toxins, as well as electrolyte imbalances and fluid retention.

The market is driven by factors such as the increasing prevalence of chronic diseases, the aging population, advancements in medical technology, and growing awareness. Market expansion has been fueled by advancements in renal insufficiency diagnoses, therapies, and treatments. Patient outcomes have improved due to technologies like better dialysis techniques and the development of new drugs.

Dynamics

Active Major Players

In May 2023, for the discovery, development, and commercialization of an antisense oligonucleotide (ASO) medication for a rare, severe chronic kidney disease with a substantial unmet medical need, Chinook Therapeutics, Inc. Inc. inked a collaboration agreement with Ionis Pharmaceuticals, Inc. The businesses will make use of Ionis' vast experience in RNA-targeted therapies and Chinook's substantial precision medicine approach and profound expertise in nephrology.

While pursuing their mission to eliminate dialysis and transplant for those with kidney disease, the development of an ASO treatment improves their capacity to target important genetic and molecular drivers and broadens their precision medicine pipeline for rare severe chronic kidney illnesses.

The Increasing Research Activities

In February 2023, a plasmid DNA contract development and manufacturing organization (CDMO) relationship between Charles River Laboratories International, Inc. and Purespring Therapeutics, a cutting-edge gene therapy business focused on revolutionizing the treatment of kidney illnesses.

The program makes use of Charles River's established plasmid platform, eXpDNA, and decades of experience at the Company's plasmid DNA manufacturing center of excellence to support the first gene therapy platform targeting renal diseases, which affect about 840 million people, or roughly 10% of the global population.

With the exception of dialysis or transplantation, Purespring is working to create innovative medicines that have the potential to halt or dramatically slow down the progression of chronic renal disorders.

Increasing Collaboration Among Key Players

In July 2022, Roche is handing over $55 million for the licensing rights to Ionis Pharmaceuticals’ rare kidney disease treatment candidate, an investigational med the Big Pharma plans to advance into a phase 3 clinical trial. Roche is taking on the California biotech’s antisense medicine dubbed IONIS-FB-LRx, which takes aim at hard-to-treat disease immunoglobulin A nephropathy, or IgAN, a rare condition that often results in chronic kidney disease and renal failure.

Under the most recent deal, Roche will be responsible for the phase 3 study of IONIS-FB-LRx in patients with IgAN, along with any future global development, regulatory and commercialization activities related to the med.

Technological Advancements

In the future, chronic kidney disease (CKD), which now kills a large number of people worldwide, is expected to overtake all other causes of death. Patients with end-stage renal disease (ESRD) are not receiving the best care possible as a result of the lack of available kidney donors and the problems related to dialysis. However, recent advancements in nephrology provide promise for the discipline.

Improvements in renal function estimation techniques, improvements in kidney imaging techniques, and novel therapeutic strategies such as wearable prosthetic kidneys, xenotransplantation, stem cell-derived therapies, bioengineering models, and new pharmaceuticals are some of these.

High Treatment Cost

In fact, the therapy of renal insufficiency, including acute kidney injury (AKI) and chronic kidney disease (CKD), is severely constrained by high treatment costs. Treatment costs for renal insufficiency can be a barrier to receiving appropriate care and have a variety of negative effects on patients, healthcare systems, and economies.

Renal insufficiency patients frequently need continuing medical care, which may include prescription drugs, routine doctor visits, laboratory tests, and sometimes dialysis or transplantation. Patients may find these expenses to be unmanageable, especially if they lack health insurance.

Drug Development Challenges

The filtration, reabsorption, secretion, and control of numerous chemicals are all sophisticated physiological processes carried out by the kidneys. Renal insufficiency develops and worsens as a result of disruptions in these processes. Due to the interconnection of various networks, it is difficult to create medications that target particular pathways while limiting off-target effects.

There are not many surrogate endpoints that can accurately predict clinical outcomes for many renal disorders. Due to this, evaluating the efficacy of experimental treatments during clinical trials is challenging.

Segment Analysis

The global renal insufficiency market is segmented based on treatment type, disease stage, sales channel, and region.

The Chronic Kidney Disease (CKD) Stages segment accounted for approximately 43.7% of the market share

According to the degree of kidney function, which is frequently assessed using the glomerular filtration rate (GFR), chronic kidney disease (CKD) is typically divided into stages. The severity of renal disease can be evaluated using the CKD stages, which also serve to direct therapy choices. A more general term, renal insufficiency, includes CKD and other degrees of decreased kidney function. Kidney Damage with Normal or Increased GFR is Stage 1 CKD, 90 mL/min GFR, Despite the fact that there is kidney damage, which can be shown in abnormalities in the urine or on imaging tests, the GFR is still within the normal range.

CKD stage two: Mild reduction in GFR. GFR is 60 to 89 mL/min. Kidney damage may still be evident, and kidney function has been slightly decreased. Moderate GFR Decrease in Stage 3 CKD. Stage 3 is broken down into two smaller stages: GFR = 45-59 mL/min in stage 3a., and GFR = 30-44 mL/min in stage 3b. Patients may begin to experience symptoms including fatigue and fluid retention due to the noticeably diminished kidney function. The goal of treatment is to control problems and halt progression.

Geographical Penetration

Advanced Healthcare Infrastructure and Active Major Players

North America has been a dominant force in the global Renal Insufficiency market. For instance, in January 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being researched as a potential treatment to lower the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).

For the estimated 37 million Americans living with CKD, this application acceptance represents a significant step forward. The sNDA is predicated on findings from the historic EMPA-KIDNEY phase III trial, which showed that Jardiance significantly decreased the risk of kidney disease progression or cardiovascular death in individuals with CKD by 28% (ARR: 3.8%) compared with placebo, both in addition to standard of treatment.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global renal insufficiency market. Healthcare services were interrupted as a result of the COVID-19 pandemic, including non-urgent medical procedures and appointments that were postponed or canceled. This might have an impact on how quickly renal insufficiency is managed.

People with renal insufficiency are thought to be at a high risk of experiencing severe COVID-19 outcomes, especially those who are on dialysis or have advanced CKD. To protect these patients, healthcare organizations had to put in place stringent infection control procedures.

Patients' access to healthcare institutions and ability to obtain in-person care were hindered by lockdowns and limitations. Although virtual consultations and telemedicine have become more popular, not all facets of renal treatment can be handled remotely.

Russia-Ukraine War Impact Analysis

The healthcare system in conflict-affected areas can be under strain if there is a major rise in casualties or displaced people, which could have an impact on the resources available for treating renal insufficiency. Access to basic renal treatment, such as routine dialysis, medication, and doctor's appointments, could be hampered by population displacement, destruction of healthcare facilities, and general instability.

The dispute may have an immediate impact on healthcare workers, which could result in a potential scarcity of qualified personnel for delivering renal care.

By Treatment Type
• Medications
• Dialysis
• Kidney Transplantation
• Others

By Disease Stage
• Chronic Kidney Disease (CKD) Stages
• End-Stage Renal Disease (ESRD)

Sales Channel
• By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
• By End-users
Dialysis Centres
Hospital & Clinics
Research & Academic Institutes

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In May 2023, Healthy.io, the global leader in transforming the smartphone camera into a medical device, launched a program with Boehringer Ingelheim Pharmaceuticals, Inc, a leading research-driven pharmaceutical company, that will support at-home testing and offer educational information for patients at risk of chronic kidney disease.

Competitive Landscape
The major global players in the market include Healthy.io, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Roche, Charles River Laboratories International, Inc., Purespring Therapeutics, Chinook Therapeutics, Inc. Inc, AstraZeneca, Baxter, and Nipro Corp.

Why Purchase the Report?
• To visualize the global renal insufficiency market segmentation based on treatment type, disease stage, sales channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Renal Insufficiency market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Renal Insufficiency market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies